Upregulation of the long non-coding RNA CBR3-AS1 predicts tumor prognosis and contributes to breast cancer progression.

Q3 Biochemistry, Genetics and Molecular Biology

Gene: X Pub Date : 2019-03-25 eCollection Date: 2019-06-01 DOI:10.1016/j.gene.2019.100014

Lingyun Xu, Hong Zhu, Fei Gao, Yinghua Tang, Yajun Zhu, Zhiqiang Sun, Jian Wang

{"title":"Upregulation of the long non-coding RNA CBR3-AS1 predicts tumor prognosis and contributes to breast cancer progression.","authors":"Lingyun Xu, Hong Zhu, Fei Gao, Yinghua Tang, Yajun Zhu, Zhiqiang Sun, Jian Wang","doi":"10.1016/j.gene.2019.100014","DOIUrl":null,"url":null,"abstract":"<p><p>Breast cancer is the most common female malignancy and the major cause of cancer-related death in women. Long non-coding RNAs (lncRNAs), as oncogenic or tumor suppressor factor, involved in the development and progression of various cancers. In this study, we sought to investigate the function of lncRNA CBR3-AS1 in breast cancer. We evaluated the expression pattern of CBR3-AS1 in breast cancer tissues and cell lines, explored the correlation between CBR3-AS1 expression and the survival time of breast cancer patients, and probed the effect of CBR3-AS1 on tumor progression of breast cancer through loss-of-function and gain-of-function strategies. Our results showed that CBR3-AS1 was overexpressed in breast cancer tissues and cell lines and predicted the prognosis of breast cancer patients. And CBR3-AS1 exerted biological function as an oncogenic lncRNA, involved in the regulation of cell proliferation, colony formation, apoptosis and tumor growth in breast cancer. Taken together, CBR3-AS1 was up-regulated in breast cancer and promoted the risk of breast cancer. It may be a novel therapeutic target and potential prognostic marker for breast cancer.</p>","PeriodicalId":37140,"journal":{"name":"Gene: X","volume":"2 ","pages":"100014"},"PeriodicalIF":0.0000,"publicationDate":"2019-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285981/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gene: X","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.gene.2019.100014","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2019/6/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}

引用次数: 0

Abstract

Breast cancer is the most common female malignancy and the major cause of cancer-related death in women. Long non-coding RNAs (lncRNAs), as oncogenic or tumor suppressor factor, involved in the development and progression of various cancers. In this study, we sought to investigate the function of lncRNA CBR3-AS1 in breast cancer. We evaluated the expression pattern of CBR3-AS1 in breast cancer tissues and cell lines, explored the correlation between CBR3-AS1 expression and the survival time of breast cancer patients, and probed the effect of CBR3-AS1 on tumor progression of breast cancer through loss-of-function and gain-of-function strategies. Our results showed that CBR3-AS1 was overexpressed in breast cancer tissues and cell lines and predicted the prognosis of breast cancer patients. And CBR3-AS1 exerted biological function as an oncogenic lncRNA, involved in the regulation of cell proliferation, colony formation, apoptosis and tumor growth in breast cancer. Taken together, CBR3-AS1 was up-regulated in breast cancer and promoted the risk of breast cancer. It may be a novel therapeutic target and potential prognostic marker for breast cancer.

查看原文本刊更多论文

长非编码 RNA CBR3-AS1 的上调可预测肿瘤的预后，并有助于乳腺癌的进展。

乳腺癌是最常见的女性恶性肿瘤，也是女性因癌症死亡的主要原因。长非编码 RNA（lncRNA）作为致癌或抑癌因子，参与了多种癌症的发生和发展。在这项研究中，我们试图研究lncRNA CBR3-AS1在乳腺癌中的功能。我们评估了CBR3-AS1在乳腺癌组织和细胞系中的表达模式，探讨了CBR3-AS1表达与乳腺癌患者生存时间的相关性，并通过功能缺失和功能获得策略探讨了CBR3-AS1对乳腺癌肿瘤进展的影响。结果表明，CBR3-AS1在乳腺癌组织和细胞系中过表达，可预测乳腺癌患者的预后。CBR3-AS1作为一种致癌lncRNA，参与调控乳腺癌的细胞增殖、集落形成、细胞凋亡和肿瘤生长。综上所述，CBR3-AS1 在乳腺癌中上调，并增加了乳腺癌的风险。它可能是乳腺癌的一个新的治疗靶点和潜在的预后标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Gene: X Biochemistry, Genetics and Molecular Biology-Genetics

自引率

0.00%

发文量